Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products for neurology, pain, and other central nervous system conditions and diseases. The company offers Gralise tablet, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; Zipsor, an oral liquid filled capsule formulation of diclofenac potassium for the treatment of mild to moderate acute pain; and Glumetza metformin hydrochloride extended release tablet that are used as a once-daily treatment for adults with type 2 diabetes. Its product pipeline also comprises Serada, which completed three Phase III clinical trials for the treatment of menopausal hot flashes; and DM-1992 that is in Phase II clinical trials for the treatment of Parkinson's disease. The company sells its Gralise products to wholesalers and retail pharmacies. It has collaboration or license arrangements with Merck & Co., Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Covidien, Ltd.; Patheon Puerto Rico, Inc.; Valeant Pharmaceuticals International, Inc.; and PharmaNova, Inc. The company was founded in 1995 and is based in Menlo Park, California.